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Sickle cell disease (SCD) is a monogenic disease that causes a
signiﬁcant reduction in life expectancy due to the presence of
chronic anemia, acute painful episodes and organic injuries.
The most common chronic injuries are cardiopulmonary com-
plications, such as pulmonary hypertension (HP), chronic lung
disease, diastolic dysfunction and congestive heart failure
(CHF), which are manifested mostly in adulthood.
These complications are associated with early mortality.
With the improvement of the healthcare system and greater
access to proper treatment, there is a growing interest in
identifying complications as early as possible by evaluating
patients in childhood and adolescence in order to improve
morbidity and mortality rates.1
Patients tend to have increased left ventricular (LV) stiff-
ness with consequent left ventricular hypertrophy (LVH) and
progression to increased high pulmonary blood pressure.
Another complication due to LVH is diastolic dysfunction, an
early marker of cardiac impairment preceding CHF that is fre-
quently found in adults with SCD.2
The pathophysiologic mechanism of HP in individuals with
SCD has not been well deﬁned but is probably multifactorial.
Potential etiologic factors include hemolysis that interferes
with nitric oxide-mediated vasodilatation, LV dysfunction,
pulmonary thromboembolism, airway hyperreactivity, and
sleep-disordered breathing.3 A high cardiac output and high
pulmonary blood ﬂow, combined with intravascular hemolysis
promote these structural changes.4The incidence of HP in the pediatric population ranges from
11% to 30%. In a paper published by Colombatti et al., there
is conﬁrmation that HP starts early in children showing the
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need for early and systematic assessments in this population.5
This paper also showed that diastolic dysfunction occurred in
children with SCD.
In the current issue of the Revista Brasileira de Hematolo-
gia e Hemoterapia, there is an article entitled “Left ventricular
hypertrophy in children, adolescents and young adults with
sickle cell anemia” by Faro et al. In this article the authors
aimed to estimate the frequency of LVH in children, adoles-
cents and young adults with sickle cell anemia.6
Of the 109 patients enrolled in this study, 37.6% had LVH.
SCD patients had high rates of LV mass as seen in other
populations. The size of the left atrium, another aspect of
cardiac complications and a potential marker of diastolic
dysfunction, was signiﬁcantly larger in patients with LVH.
The authors showed an association between this condition
and low hemoglobin and hematocrit levels, a low reticulo-
cyte index and a higher albumin:creatinine ratio. Hemolysis
markers (lactate dehydrogenase, indirect bilirubin and fer-
ritin) were statistically similar with high values in both
groups.6
Unfortunately, this paper did not conﬁrm any protective
effect of hydroxyurea, but the authors hypothesized that this
may be related to the small number of patients who  were tak-
ing the drug. Clinical trials with larger numbers of patients
may help to clarify the role of hydroxyurea in the treatment
of these complications.
This paper demonstrates that the population of patients–8.
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with SCD presented cardiac complications at an earlier age
and that the association of clinical signs and symptoms may
guide us.6
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